Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

Pfizer said its blood-cancer treatment met the main goal of an ongoing late-stage study, significantly extending the time patients lived without their disease worsening compared with a standard drug ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Pfizer has shared promising phase 2 results of its Elrexfio (elranatamab-bcmm) monotherapy in patients with heavily pre-treated relapsed or refractory multiple myeloma (RRMM) as part of its ongoing ...

Pfizer’s multiple myeloma drug Elrexfio met its main goal in a late-stage trial, delivering a statistically significant and clinically meaningful improvement in progression-free survival over standard ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily ...

Pfizer reported that its multiple myeloma therapy Elrexfio met the primary goal in a late-stage study, significantly extending progression-free survival for patients who had received at least one ...